This is my TAKHZYRO
EXPERIENCE

Imagine what the #1 PRESCRIBED HAE preventive treatment* can mean for your patients

TAKHZYRO is clinically proven to help prevent HAE attacks, and patients experienced long-term freedom from attacks for an average of 14.8 months.1,2

  • Evaluated in a 6.5-month study and a 2.5-year open-label extension (OLE) study
  • Mean duration of the attack-free period in the OLE study was 14.8 (SD=12.4) months (N=209)
*Based on total patients on HAE preventive treatments according to US third-party industry healthcare data. †The number of patients prescribed TAKHZYRO is based on third-party US specialty pharmacy data.
imageoverlay

Dennis

Real TAKHZYRO Patient since 2018

I want to learn about:

efficacy
safety
dosing
Style
Inner-content-contained, background-lavender-light, section-no-top-margin, section-no-bottom-margin, section-learn-about

Rediscover effective prevention

The safety and efficacy of TAKHZYRO (lanadelumab-flyo) were assessed in a 6.5 months pivotal trial of 125 HAE patients ≥12 years of age. The primary efficacy endpoint was the rate of investigator-confirmed attacks during the treatment period compared to placebo.1,4

help study design

Significant reduction in mean attack rate‡ vs placebo at 6.5 months in the HELP study1,4

87% reduction in attacks vs placebo (Adjusted P<0.001)
  • TAKHZYRO 300 mg every 4 weeks resulted in a 73% reduction in attacks vs placebo (Adjusted P<0.001)1§

Mean monthly attack rate during the run-in period4:

3.52
for Q2W arm (n=27)		 3.71
for Q4W arm (n=29)		 4.02
for placebo arm (n=41)

Mean monthly attack rate during the treatment period1:

0.26
for Q2W arm		 0.53
for Q4W arm		 1.97
for placebo arm

All data presented are for TAKHZYRO 300 mg every 2 weeks unless otherwise indicated.1
‡Mean monthly attack rate: number of attacks/4 weeks.1
§Adjusted P-values for multiple testing.1

Q2W=every 2 weeks; Q4W=every 4 weeks.

HELP study: A multicenter, double-blind, parallel group, placebo-controlled clinical study assessed the efficacy and safety of TAKHZYRO in 125 HAE Type I/II patients (≥12 years of age) for 6.5 months. Patients were treated with TAKHZYRO 150 mg q4wks, TAKHZYRO 300 mg q2wks, TAKHZYRO 300 mg q4wks, or placebo. Primary endpoint: rate of investigator-confirmed attacks during the treatment.1,4

Style
inner-content-contained, tak-effective-prevention, section-no-bottom-margin, section-no-top-margin, section-no-bottom-padding

The 6.5-month HELP clinical trial of 125 patients led to the 2018 FDA approval of TAKHZYRO

STUDIED IN OVER

800

PATIENTS GLOBALLY3
ACROSS 15 STUDIES

STUDIED FOR

11

YEARS IN US CLINICAL AND REAL-WORLD STUDIES3

PRESCRIBED TO OVER

4000

US PATIENTS SINCE 20183‖

||Based on third-party US specialty
pharmacy data.

Style
inner-content-contained, footnote, tak-effective-prevention-columns

Help your patients get started and stay on track with TAKHZYRO.

patient resources

Style
Inner-content-contained, background-lavender-light, section-no-top-margin, section-no-bottom-margin

References: 1. Takhzyro. Prescribing information. Dyax Corp; 2023. 2. Banerji A, Bernstein JA, Johnston DT, et al; HELP OLE Investigators. Allergy. 2022;77(3):979-990. doi:10.1111/all.15011 3. Data on File, TAKHZYRO DOF, Takeda Pharmaceuticals USA, Inc. 4. Banerji A, Riedl MA, Bernstein JA, et al. JAMA. 2018;320(20):2108-2121. doi:10.1001/jama.2018.16773

Style
Inner-content-contained, section-references, section-no-top-margin, section-no-bottom-margin
https://main--takeda-eds-sites-takhzyro--onetakeda.hlx.page/hcp/fragments/isi
Style
Inner-content-contained, section-no-margin
id
important-safety-information